Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Miguel F Sanmamed 1 2 3 4 , Pedro Berraondo 1 2 4 , Maria E Rodriguez-Ruiz 1 2 3 , Ignacio Melero 5 6 7 8
Checkpoint inhibitor-based cancer immunotherapy is often combined in the clinic with other immunotherapy strategies, targeted therapies, chemotherapy or standard-of-care treatments to achieve superior therapeutic efficacy.
The large number of immunotherapy combinations that are currently undergoing clinical testing necessitate the establishment of faithful criteria to prioritize optimal combinations with evidence of synergy, to determine their safety and optimal sequence of administration and to identify biomarkers of therapy resistance and response.
In this review, we focus on recent developments in immunotherapy combinations and reflect on how combinations should be optimized to maximize the impact of immunotherapy in clinical oncology.